Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + Trastuzumab + Chemotherapy in HER2+ Gastric Cancer
NCT05311189Phase 2Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Apr 2022
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of serplulimab in Gastric cancer (HER2-positive), sponsored by Zhongshan Hospital, Fudan University. Status: unknown.
02
Drugs
serplulimab
03
Conditions
Gastric cancer (HER2-positive)
Beyond the preview
Go deeper on NCT05311189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05311189.